

# Medical Office Update

August

## In this issue

- Vitamin D coverage change
- Provider Workshops
- Updated Commercial Provider Manual
- Auto Auth Application reminder
- Magellan Rx name change
- Biosimilar Basics: FDA Purple Book
- Reimbursement Policy updates
- Medical Necessity criteria updates

## Join our email list

Join our email list in order to begin receiving bi-monthly newsletters, as well as occasional electronic communications.

Sign up now

## Changes to Vitamin D testing coverage

Starting Oct. 1, 2024, coverage for Vitamin D testing will be limited to diagnosis codes approved in our medical necessity criteria. Claims billed without a diagnosis code listed in Appendix 1 of the [medical necessity criteria – Vitamin D Testing](#) will be denied.

This policy change applies to laboratory tests billed with CPT codes 0038U, 82306, and 82652. Please see our medical necessity criteria for details.

---

## See what's new for 2024-25

Moda Health's Provider Relations team invites you to join our free, online provider workshops, starting Oct. 17th.

Our fall workshops will be held virtually and will cover various topics, such as:

- Network update and changes
- Policy updates
- Claim billing and appeals
- Quality and value-based care programs
- Behavioral health (for all states)

### Register today!

Don't miss out! Visit our [provider workshop page](#) and choose the workshop that best fits your schedule. Each workshop will last about an hour.

---

## Discover our enhanced Commercial Provider Manual

We've made important updates and key enhancements to our Commercial Provider Manual. These changes make it easier and more helpful for you, allowing you to navigate our services more effectively.

Visit our [Policies and manuals website](#) to view the revised manual. Stay current with these updates to ensure you have the latest, most accurate information at your fingertips.

---

## Auto Auth Application reminder

We're excited to share some changes to our prior authorization submission process. We've implemented a new Auto Authorization Application that now lets you submit prior authorizations for Moda Health members electronically through our Benefit Tracker tool, making your experience smoother and more efficient.

All Benefit Tracker users can access the new Auto Authorization Application. If you or your staff need access, please [visit our website](#) to learn how to enroll.

### How to submit a request with the Auto Authorization Application

Once you're in Benefit Tracker, follow these steps to submit a request.

1. Find the member's benefit profile and look for the new "Prior Authorization" option under "Medical Benefits."
2. Before submitting, we recommend reviewing the prior authorization list. The link is available on the "Prior Authorization" landing page, which includes instructions on how to submit your request by line of business.
3. Click the "Create New Request" button to submit your authorization.
4. Once you've submitted the request, you can view your request history and request status on the "Prior Authorization" landing page.

As a valued partner of Moda Health, we thank you for helping our members to better health and wellness.

---

## Magellan Rx Management is changing its name

On Oct. 1, 2024, Magellan Rx Management will become Prime Therapeutics Management.

Prime will roll out new branding on provider materials, including letters, its provider portal (MRxGateway.com), and phone greetings in early September. Please keep using the current provider portal until you're redirected to the new URL in October. You won't need to re-register and can expect the same easy navigation and functionality, but with a new name, look and feel.

If you have any questions, please email the Prime Medical Pharmacy Solutions Provider Relations team at [ProviderInquiry@PrimeTherapeutics.com](mailto:ProviderInquiry@PrimeTherapeutics.com).

---

## The FDA Purple Book: Your go-to biosimilar guide

Dear Provider,

Biosimilar use remains a hot topic in healthcare. To help doctors navigate this growing field, the FDA Purple Book is a great resource for prescribing a biological product, including biosimilars.<sup>1</sup>

**What is the Purple Book?** It's a database with details about all FDA-licensed biological products regulated by the Center for Drug Evaluation and Research (CDER), including biosimilars and their reference products.<sup>1</sup> You can find the Purple Book on the [FDA's website](#).

What's the difference between a reference product and a biosimilar product?

- A reference product is the original medicine approved by the FDA with complete safety and effectiveness data. **Example:** Humira (adalimumab)
- A biosimilar product is very similar to a reference product and works just as safely and effectively. **Examples:** Hadlima (adalimumab-bwwd) and Hyrimoz (adalimumab-adaz)

### **Does an interchangeability biosimilar work better or more safely than a non-interchangeable biosimilar?**

No, the FDA says both types of biosimilars are just as safe and effective as the original product. Interchangeable biosimilars are designed to be easily substituted at the pharmacy, but they don't work better or more safely than non-interchangeable biosimilars.

### **What is the Purple Book status of Moda Health's preferred biosimilar products?**

Hadlima (adalimumab-bwwd) and adalimumab-adaz are the preferred Humira biosimilars on the Moda Health formulary. The FDA's Purple Book shows that Hadlima and adalimumab-adaz are similar to Humira, offering safe and effective treatment. These biosimilars represent a high-value treatment option for patients who are established on Humira or new to treatment.<sup>2</sup>

### **Questions? We're here to help!**

Learn more about biosimilars at the [FDA's biosimilars webpage](#) or call our Moda Health Pharmacy Customer Service team at **888-361-1610**.

As always, we appreciate your support in helping our members to better health and wellness.

Sincerely,  
Moda Health

---

#### References:

1. U.S. Food and Drug Administration. Purple book: Database of licensed biological products. Updated June 28, 2024. Accessed July 12, 2024. <https://purplebooksearch.fda.gov/>
2. U.S. Food and Drug Administration. 9 Things to Know About Biosimilars and Interchangeable Biosimilars. Updated June 20, 2024. Accessed July 12, 2024. <https://www.fda.gov/drugs/things-know-about/9-things-know-about-biosimilars-and-interchangeable-biosimilars#:~:text=FDA%2Dapproved%20biosimilars%20and%20interchangeable,as%20living%20cells%20or%20microorg anisms>

## February Additional Information

Looking for additional information about this month's topics? Click the button below for our new comprehensive document. This month it will contain:

- [Reimbursement Policy Manual updates for June – July 2024](#)
- [Medical Necessity Criteria](#)

---

### Moda Health Medical Customer Service

For claims review, adjustment requests and/or billing policies, please call 888-217-2363 or email [medical@modahealth.com](mailto:medical@modahealth.com).

Moda Health Plan, Inc. | 601 S.W. Second Avenue, Portland, OR 97204

[modahealth.com](http://modahealth.com)

[View this email in a browser.](#)

[Sent to . Privacy and Transparency Center | Manage Preferences](#)